TG Therapeutics
Patents, Design & Utilities

Last updated:

List of all TG Therapeutics patents 6 in total

Status Patent
Application
Utility: TRIPLE COMBINATION TO TREAT B-CELL MALIGNANCIES External link
Filling date: 6 Sep 2025 Issue date: 12 May 2022
Application
Utility: COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBITOR TO TREAT B-CELL PROLIFERATIVE DISORDERS External link
Filling date: 6 Sep 2025 Issue date: 10 Jun 2021
Grant
Utility: Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders External link
Filling date: 6 Sep 2025 Issue date: 6 Apr 2021
Application
Utility: Combination of Anti-CD20 Antibody and PI3 Kinase Selective Inhibitor External link
Filling date: 6 Sep 2025 Issue date: 15 Oct 2020
Grant
Utility: Combination of anti-CD20 antibody and PI3 kinase selective inhibitor External link
Filling date: 6 Sep 2025 Issue date: 4 Aug 2020
Application
Utility: COMBINATION OF AN ANTI-CD20 ANTIBODY, PI3 KINASE-DELTA INHIBITOR, AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY FOR TREATING HEMATOLOGICAL CANCERS External link
Filling date: 6 Sep 2025 Issue date: 15 Aug 2019

Showing 1 to 6 of 6 patents.